Benitec Biopharma Share Holder Equity 2014-2022 | BNTC
Benitec Biopharma share holder equity from 2014 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Benitec Biopharma Annual Share Holder Equity
(Millions of US $) |
| 2021 |
$20 |
| 2020 |
$10 |
| 2019 |
$17 |
| 2018 |
$15 |
| 2017 |
$16 |
| 2016 |
$14 |
| 2015 |
$20 |
| 2014 |
$31 |
| 2013 |
$1 |
Benitec Biopharma Quarterly Share Holder Equity
(Millions of US $) |
| 2022-03-31 |
$8 |
| 2021-12-31 |
$11 |
| 2021-09-30 |
$15 |
| 2021-06-30 |
$20 |
| 2021-03-31 |
$11 |
| 2020-12-31 |
$15 |
| 2020-09-30 |
$8 |
| 2020-06-30 |
$10 |
| 2020-03-31 |
|
| 2019-09-30 |
|
| 2017-09-30 |
$15 |
| 2016-09-30 |
$15 |
| 2016-06-30 |
$14 |
| 2016-03-31 |
$18 |
| 2015-12-31 |
$20 |
| 2015-06-30 |
$20 |
| 2014-12-31 |
$25 |
| 2014-06-30 |
$31 |
| 2013-06-30 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.007B |
$0.000B |
|
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
|
